Global Capacity CiVentiChem has expanded production capacity in 2024 to handle programs from gram-scale synthesis to multi-ton manufacturing, signaling readiness for larger client engagements and scale-up collaborations in early discovery through commercial production.

US Presence With a Cary, North Carolina office to streamline shipping and communication for US-based clients, there is a clear pathway for closer engagement, faster timelines, and easier regulatory coordination for American customers.

End-to-End Support As a CDMO covering medicinal chemistry, process chemistry, and Regulatory Starting Materials, CiVentiChem offers integrated services across the development funnel, presenting opportunities to upsell from discovery chemistry to scale-up and GMP manufacturing.

Strategic Acquisition The 2019 US acquisition by Sterling Pharma Solutions and ongoing global operations suggest a resilient business model with potential cross-sell opportunities to Sterling’s network and aligned CDMO partnerships.

Regulatory Readiness Experience with RSMs and intermediates positions CiVentiChem to target sponsors needing compliant, scalable supply chains, reducing regulatory risk for manufacturers seeking reliable sourcing for regulatory starting materials.